Pivotal phase III trial investigating galactomannan-C (DAVANAT) in combination with standard chemotherapy in patients with metastatic colorectal cancer.

Trial Profile

Pivotal phase III trial investigating galactomannan-C (DAVANAT) in combination with standard chemotherapy in patients with metastatic colorectal cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 15 May 2012

At a glance

  • Drugs Galactomannan C (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Galectin Therapeutics
  • Most Recent Events

    • 15 May 2012 This rial does not appear to have begun in 2011 as planned.
    • 11 Jan 2011 Agreement for the design of this pivotal trial has been reached between the US FDA and Pro-Pharmaceuticals.
    • 11 Jan 2011 Planned initiation date changed to 1 Jan 2011, based on information in a media release from Pro-Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top